This newsletter presents you the following key sessions:
1. Podcast with Dr. Sibylle Loibl about the last results of the KATHERINE trial comparing adjuvant ado-
trastuzumab emtansine and trastuzumab for the treatment of residual invasive HER2-positive early
breast cancer
2. Pembrolizumab plus olaparib after induction with pembrolizumab and chemotherapy for locally recurrent
inoperable or metastatic TNBC
3. Datopotamab deruxtecan superior to chemotherapy in patients with endocrine resistant HR+/HER2-
advanced breast cancer
4. Adding avelumab to vinorelbine plus trastuzumab improves the progression-free survival in heavily
pre-treated patients with HER2+ metastatic breast cancer
5. Exercise can markedly improve the quality of life for patients with metastatic breast cancer